Breast cancer (invasive) · None

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	aggressive
Linked regimen	`None`

ID	`IND-BRCA-CARRIER-INTENSIFIED`
Type	Indication
Status	reviewed 2026-05-18 \| pending_clinical_signoff
Diseases	`DIS-BREAST`
Sources	`SRC-NCCN-BREAST-2025` `SRC-NCCN-GENETIC-FAMILIAL-BREAST-OVARIAN-2025` `SRC-NCCN-OVARIAN-2025`

Notes

STUB — v0.2-B confirmed-carrier intensified track (BRCA). Sibling — IND-BRCA-CARRIER-SURVEILLANCE (standard plan_track). §15.2 C4 ≥2-tracks invariant compliance.

Used By

Actionability

BMA-AMH-OVARIAN-RESERVE-BSO-TIMING - Anti-Müllerian Hormone (AMH) reflects primordial follicle pool size and is the best singl...

Algorithms

ALGO-HEREDITARY-PROSTATE-CANCER-RISK - ALGO-HEREDITARY-PROSTATE-CANCER-RISK

Indication

IND-BRCA-CARRIER-SURVEILLANCE - IND-BRCA-CARRIER-SURVEILLANCE
IND-CASCADE-BRCA-FDR-POSITIVE-TESTING - IND-CASCADE-BRCA-FDR-POSITIVE-TESTING

Red flag

RF-BRCA-CONFIRMED-CARRIER - Confirmed germline pathogenic / likely-pathogenic variant in BRCA1 or BRCA2 — the canonic...